arrow
N

Nunzio Sciammetta

pfizer united kingdom
H指数:15
被引数:751

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diminishing GSH-Adduct Formation of Tricyclic Diazepine-basedMutant IDH1 Inhibitors
2022-03-283
OA
Oxetane Promise Delivered: Discovery of Long-Acting IDO1Inhibitors Suitable for Q3W Oral or Parenteral Dosing
2022-03-0311
PRE
Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors
2021-02-2617
OA
Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors

发现有效且可口服的双环 [1.1.1] 戊烷衍生的Indoleamine-2,3-双加氧酶1 (IDO1) 抑制剂

2020-07-1557
OAAI
Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1)

在Indoleamine-2,3-双加氧酶-1 (IDO1) 的血红素置换抑制剂中战略性地掺入极性

2020-03-1028
OAAI
Discovery of N-(Indazol-3-yl)piperidine-4-carboxylic Acids as RORγt Allosteric Inhibitors for Autoimmune Diseases
2020-01-0920
OAAI
Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy

发现用于癌症免疫疗法的氨基-环丁基芳烃衍生的Indoleamine-2,3-双加氧酶1 (IDO1) 抑制剂

2019-09-1838
OAAI
Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles
2017-05-0520
PREAI
Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit
2012-11-08209
OAAI